Compare Regeneron Pharmaceuticals Inc (REGN) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.91 (market cap $3.39B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 22.5× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days on average.
| REGN | SPUS | |
|---|---|---|
Market Cap | $76.40B | $3.39B |
Volume | 626,381 | 356,227 |
Sector | Health | Broad Market / Factor |
52-Week High | $852.03 | $61.15 |
52-Week Low | $557.73 | $46.65 |
Typical Hold Time | 107 Days | 64 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $61.07, down 0.13% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows consistent dividend payments of $0.03 monthly through mid-2026. Short interest surged 174.5% to 257,142 shares in September 2026, indicating growing bearish sentiment among some investors despite the overall technical strength.
The ETF's outlook remains mixed with strong technical momentum countered by elevated short interest and overbought RSI levels. Investment opportunity lies in Sharia-compliant S&P 500 exposure, while risks include concentrated short positioning and potential mean reversion from current technical extremes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
